Log In Sign up
The largest database of trusted experimental protocols

Beh300 c4 reverse phase column

Manufactured by Waters Corporation
Visit Supplier

The BEH300 C4 reverse-phase column is a laboratory equipment product designed for high-performance liquid chromatography (HPLC) applications. The column features a bonded C4 stationary phase and a wide pore size of 300 Å, making it suitable for the separation and analysis of a variety of biomolecules, including proteins and peptides. The core function of this column is to facilitate the separation and purification of complex samples through reversed-phase chromatography.

Automatically generated - may contain errors

Lab products found in correlation

Ultra performance liquid chromatography (uplc), by Waters Corporation (1 mentions) Empower 3, by Waters Corporation (1 mentions) Biopharmalynx v1, by Waters Corporation (1 mentions) Masslynx v4, by Waters Corporation (1 mentions) Pngase f, by New England Biolabs (1 mentions)

2 protocols using beh300 c4 reverse phase column

1

Hydrophobicity Profiling of Eculizumab

Check if the same lab product or an alternative is used in the 5 most similar protocols
The hydrophobicity profile of eculizumab (SB12 and RP) samples was determined using 2.15 reverse phase-UPLC (RP-UPLC). Eculizumab (SB12 and RP) samples were loaded on a BEH300 C4 reverse-phase column (Waters) and separated by reverse-phase mode on UPLC (Waters) with UV detection at 280 nm. Data were acquired and processed using Empower®3 software (Waters).
Kim H., Hong E., Lee J., Hong S., Kim J., Cho M., Kim Y, & Yoo T. (2023). Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method. Biodrugs, 37(4), 569-581.
+ Open protocol
+ Expand
2

Intact Mass Analysis of Eculizumab

Check if the same lab product or an alternative is used in the 5 most similar protocols
Intact mass analysis was performed to determine MW by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS).
Glycosylated and deglycosylated whole protein mass, glycosylated and deglycosylated HC mass, and LC mass of eculizumab (SB12 and RP) were measured using a mass spectrometer after treatment or non-treatment of 1 M 1,4-Dithiothreitol (DTT) and/or PNGase F (NEB). The digested samples were loaded on a BEH300 C4 reverse-phase column (Waters) connected to Waters ultra performance liquid chromatography (UPLC)-MS. Data acquisition and processing was performed using MassLynx v4.1 (Waters) and/or BiopharmaLynx v1.2 software (Waters).
Kim H., Hong E., Lee J., Hong S., Kim J., Cho M., Kim Y, & Yoo T. (2023). Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method. Biodrugs, 37(4), 569-581.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!